Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Янв. 25, 2024
Circulating
tumor
cells
(CTCs),
circulating
DNA
(ctDNA),
and
extracellular
vehicles
(EVs)
have
received
significant
attention
in
recent
times
as
emerging
biomarkers
subjects
of
transformational
studies.
The
three
main
branches
liquid
biopsy
evolved
from
the
primary
detection
targets—CTC,
ctDNA,
EVs—each
with
distinct
benefits.
CTCs
are
derived
cancer
original
or
metastases
may
display
global
features
tumor.
ctDNA
has
been
extensively
analyzed
used
to
aid
diagnosis,
treatment,
prognosis
neoplastic
diseases.
EVs
contain
tumor-derived
material
such
DNA,
RNA,
proteins,
lipids,
sugar
structures,
metabolites.
provide
different
contents
but
strong
complementarity
a
certain
extent.
Even
though
they
already
employed
several
clinical
trials,
utility
is
still
being
studied,
promising
initial
findings.
This
review
thoroughly
overviews
established
technologies
for
isolation,
characterization,
content
CTC,
EVs.
Also
discussed
were
most
developments
study
potential
therapeutic
monitoring,
prediction.
These
included
Finally,
challenges
employing
based
on
precision
medicine
evaluated.
Язык: Английский
Impact of immune checkpoint inhibitors and local radical treatment on survival outcomes in synchronous oligometastatic NSCLC
JTO Clinical and Research Reports,
Год журнала:
2025,
Номер
6(3), С. 100790 - 100790
Опубликована: Янв. 8, 2025
The
impact
of
an
immune
checkpoint
inhibitor
(ICI)-based
systemic
treatment
strategy
with
or
without
local
radical
(LRT)
on
outcomes
for
patients
NSCLC
and
synchronous
oligometastatic
disease
(sOMD)
is
unknown.
Multicenter
retrospective
study
including
adequately
staged
patients,
sOMD
(maximum
five
metastases
in
three
organs
[European
Organization
Research
Treatment
Cancer
definition])
between
January
1,
2015
December
31,
2022,
treated
a
first-line
ICI-based
versus
chemotherapy-only
regimen.
Primary
end
points
were
progression-free
survival
overall
(OS)
strategy.
Subgroup
analyses
performed
who
deemed
candidates
LRT
the
multidisciplinary
meeting
those
proceeding
to
LRT.
A
total
416
included,
chemotherapy-ICI
(n
=
138)
278),
319
out
by
meetings
LRT,
whereas
192
(60%)
proceeded
median
OS
was
significantly
longer
compared
group
(33.6
15.9
mo,
hazard
ratio
[HR]
0.5,
95%
confidence
interval
[CI]:
0.4-0.7,
p
<
0.001),
subgroups
candidate
(36.1
17.2
HR
CI:
0.001)
(not
reached
23.1
0.4,
0.2-0.7,
0.001).
In
multivariate
analysis,
associated
improved
(HR
0.6,
0.4-0.9,
intention
0.02)
0.3,
0.1-0.6,
0.002).
An
(±LRT)
NSCLC.
Prospective
randomized
trial
data
are
necessary
identify
most
likely
benefit
from
adding
Язык: Английский
The Promise of Radiotherapy in High-Risk Non-Muscle Invasive Bladder Cancer
Cancers,
Год журнала:
2025,
Номер
17(4), С. 628 - 628
Опубликована: Фев. 13, 2025
Global
shortages,
toxicities,
and
high
levels
of
incomplete
treatment
with
Bacillus
Calmette
Guerin
(BCG)
for
non-muscle
invasive
bladder
cancer
has
resulted
in
increasing
interest
alternative
treatments.
Radiotherapy
is
not
the
standard
care
(NMIBC),
despite
being
routinely
used
muscle
cancer.
Modern
techniques
advances
technology
mean
that
radiotherapy
can
be
delivered
increased
precision
reducing
normal
tissue
damage.
Developing
novel
biomarker
approaches,
together
combination
approaches
radiosensitisers
other
systemic
treatments,
means
could
offer
greater
benefits
than
current
treatments
BCG
or
surgery.
This
review
summarises
landscape
future
potential
high-risk
NMIBC.
Язык: Английский
Mathematical modeling of radiotherapy: impact of model selection on estimating minimum radiation dose for tumor control
Frontiers in Oncology,
Год журнала:
2023,
Номер
13
Опубликована: Окт. 9, 2023
Introduction
Radiation
therapy
(RT)
is
one
of
the
most
common
anticancer
therapies.
Yet,
current
radiation
oncology
practice
does
not
adapt
RT
dose
for
individual
patients,
despite
wide
interpatient
variability
in
radiosensitivity
and
accompanying
treatment
response.
We
have
previously
shown
that
mechanistic
mathematical
modeling
tumor
volume
dynamics
can
simulate
volumetric
response
to
patients
estimation
personalized
optimal
reduction.
However,
understanding
implications
choice
underlying
model
critical
when
calculating
dose.
Methods
In
this
study,
we
evaluate
biological
effects
2
models
on
personalization:
(1)
cytotoxicity
cancer
cells
lead
direct
reduction
(DVR)
(2)
responses
microenvironment
carrying
capacity
(CCR)
subsequent
shrinkage.
Tumor
growth
was
simulated
as
logistic
with
pre-treatment
being
described
proliferation
saturation
index
(PSI).
The
effect
according
each
respective
a
standard
schedule
fractionated
Gy
weekday
fractions.
Parameter
sweeps
were
evaluated
intrinsic
rate
parameter
both
observe
qualitative
impact
parameter.
then
calculated
minimum
required
locoregional
control
(LRC)
across
all
combinations
full
range
radiosensitvity
values.
Results
Both
estimate
higher
will
require
lower
achieve
LRC.
two
make
opposite
estimates
PSI
LRC:
DVR
tumors
values
LRC,
while
CCR
Discussion
Ultimately,
these
results
show
importance
which
best
describes
particular
setting,
before
using
any
such
recommendations.
Язык: Английский
Sensitive MRD Detection from Lymphatic Fluid after Surgery in HPV-Associated Oropharyngeal Cancer
Clinical Cancer Research,
Год журнала:
2023,
Номер
30(7), С. 1409 - 1421
Опубликована: Ноя. 8, 2023
Abstract
Purpose:
Our
goal
was
to
demonstrate
that
lymphatic
drainage
fluid
(lymph)
has
improved
sensitivity
in
quantifying
postoperative
minimal
residual
disease
(MRD)
locally
advanced
human
papillomavirus
(HPV)-associated
oropharyngeal
squamous
cell
carcinoma
(OPSCC)
compared
with
plasma,
and
leverage
this
novel
biofluid
for
patient
risk
stratification.
Experimental
Design:
We
prospectively
collected
lymph
samples
from
neck
drains
of
106
patients
HPV
(+)
OPSCC,
along
67
matched
plasma
samples,
24
hours
after
surgery.
PCR
next-generation
sequencing
were
used
quantify
cancer-associated
cell-free
(cf-HPV)
tumor-informed
variants
plasma.
Next,
cf-HPV
TNM
stage,
extranodal
extension
(ENE),
composite
definitions
high-risk
pathology.
then
created
a
machine
learning
model,
informed
by
MRD
clinicopathologic
features,
compare
progression-free
survival
(PFS).
Results:
Postoperative
enriched
(P
<
0.0001)
correlated
pN2
stage
=
0.003),
ENE
0.0001),
trial-defined
pathologic
criteria
(mean
AUC
0.78).
In
addition,
the
mutation
number
variant
allele
frequency
higher
necks
than
pN1
0.03,
P
0.02)
or
pN0-N1
(−)
0.04,
respectively).
The
MRD-informed
model
demonstrated
inferior
PFS
(AUC
0.96,
0.0001).
Conclusions:
Variant
quantification,
performed
24-hour
reflects
single-
multifeature
criteria.
Incorporating
feature
analysis
can
stratify
early
surgery
head
cancer.
See
related
commentary
Shannon
Iyer,
p.
1223
Язык: Английский
Omics technologies in oral oncology: Integrative approaches for biomarker discovery and therapeutic insights
Oral Oncology Reports,
Год журнала:
2024,
Номер
10, С. 100424 - 100424
Опубликована: Апрель 23, 2024
•
Omics
technologies
provide
a
holistic
understanding
of
oral
cancer
biology
through
genomics,
transcriptomics,
proteomics,
and
metabolomics.
Combined
multi-omics
analysis
contributes
to
the
discovery
new
biomarkers
for
early
diagnosis
treatment,
creating
opportunities
improved
patient
outcomes.
support
precise
medicine
approaches
by
identifying
patient's
molecular
alterations
based
on
results
systemic
characterization.
Язык: Английский
Radiomics in colorectal cancer
iRadiology,
Год журнала:
2023,
Номер
1(3), С. 236 - 244
Опубликована: Сен. 1, 2023
Abstract
Colorectal
cancer
(CRC)
is
a
global
health
challenge
with
high
morbidity
and
mortality.
Radiomics,
an
emerging
field,
utilizes
quantitative
imaging
features
extracted
from
medical
images
for
CRC
diagnosis,
staging,
treatment
response
assessment,
prognostication.
This
review
highlights
the
potential
of
radiomics
personalized
management.
Radiomics
enables
noninvasive
tumor
characterization,
aiding
in
early
detection
accurate
it
can
be
used
to
predict
stage,
lymph
node
involvement,
prognosis.
Furthermore,
guides
therapies
by
assessing
identifying
patients
who
could
benefit.
Challenges
include
standardizing
protocols
analysis
techniques.
Robust
validation
frameworks
user‐friendly
software
are
needed
integration
into
clinical
practice.
Despite
challenges,
offers
valuable
insights
biology,
response,
prognosis
CRC.
Overcoming
technical
hurdles
will
unlock
its
full
Язык: Английский
Prognostic and predictive biomarkers in oligometastatic Non-Small Cell Lung Cancer: new insights and clinical applications
JTO Clinical and Research Reports,
Год журнала:
2024,
Номер
5(12), С. 100740 - 100740
Опубликована: Окт. 17, 2024
Язык: Английский
Emergence of Circulating Tumor DNA as a Precision Biomarker in Lung Cancer Radiation Oncology and Beyond
Hematology/Oncology Clinics of North America,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 1, 2024
Язык: Английский
Precision medicine in head and neck cancer: from immunotherapy to microbiota, circulating DNA and robotic surgery
Otorhinolaryngology,
Год журнала:
2023,
Номер
73(4)
Опубликована: Дек. 1, 2023
The
concept
of
precision
medicine
aims
to
combine
clinical
practice
with
research
data,
in
order
obtain
the
most
effective
and
personalized
treatment
strategy
for
each
individual
patient.
In
field
head
neck
oncology,
different
advancements
are
profoundly
transforming
care
cancer
patients
through
medicine.
particular,
four
key
areas
driving
innovations
this
“new”
approach
cancer:
immunotherapy
(with
a
specific
focus
on
checkpoint
inhibitors),
role
microbiota,
liquid
biopsies
circulating
DNA,
as
well
integration
robotic
surgery
daily
practice.
As
these
continues
evolve,
application
holds
promise
improving
outcomes
Quality
Life
patients,
clearing
path
more
tailored
efficient
therapies.
Язык: Английский